Estrella Immunopharma risks Nasdaq delisting after market value falls below $35 million threshold - ESLA News | RalliesEstrella Immunopharma risks Nasdaq delisting after market value falls below $35 million threshold
E
ESLA• Nasdaq notice over market value shortfall
- Estrella Immunopharma received a Nasdaq notice for failing the $35 million market value of listed securities rule.
- MVLS stayed below $35 million for 30 straight business days from July 21 through Aug. 31, 2026.
- Nasdaq also flagged noncompliance with alternative standards for stockholders’ equity or net income.
- Shares keep trading on Nasdaq Capital Market; deadline to regain compliance is March 1, 2027.
- Failure to cure by then could trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel.
YQ
•
